Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lubiprostone

FDA-approved product (capsule, oral), marketed as Amitiza, Lubiprostone.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Lubiprostone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chronic pain
  • Constipation
  • Constipation disorder
  • Irritable bowel syndrome

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other drugs for constipation
FDA pharmacologic class
Chloride Channel Activator FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli28.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis24.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lubiprostone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lubiprostone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal Cancer

    NCT07405736 · start 2026-02-24

    Registered record
    Registry ID
    NCT07405736
    Conditions
    Colorectal Cancer Metastatic; Peritoneal (Metastatic) Cancer; Peritoneal Metastasis; Colorectal Cancer (CRC); MSS Metastatic Colorectal Cancer
    Interventions
    maintenance therapy plus lubiprostone; maintenance therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-02-24
    Completion
    2028-06-01
    Enrolment
    124

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer Metastatic; Peritoneal (Metastatic) Cancer; Peritoneal Metastasis; Colorectal Cancer (CRC) +1 more
    Interventionmaintenance therapy plus lubiprostone; maintenance therapy
    PhasePhase 2
    Registry statusNot yet recruiting

  • Efficacy and Safety of Lubiprostone in the Treatment of Slow Transit Constipation

    NCT07277907 · start 2025-11-13

    Registered record
    Registry ID
    NCT07277907
    Conditions
    Slow Transit Constipation; Pharmacotherapy
    Interventions
    Lubiprostone; Polyethylene glycol (PEG )
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-11-13
    Completion
    2027-11-30
    Enrolment
    346

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSlow Transit Constipation; Pharmacotherapy
    InterventionLubiprostone; Polyethylene glycol (PEG )
    PhasePhase 3
    Registry statusRecruiting

  • Anorectal Manometery in Pediatric Chronic Refractory Constipation

    NCT06543979 · start 2024-09-07

    Registered record
    Registry ID
    NCT06543979
    Conditions
    Chronic Constipation
    Interventions
    lubiprostone , single arm; biofeed back sessions; botox injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2024-09-07
    Completion
    2025-10-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Constipation
    Interventionlubiprostone , single arm; biofeed back sessions; botox injection
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Lubiprostone for Functional Constipation in the Under 18 Years Patients

    NCT05144295 · start 2022-01-01

    Registered record
    Registry ID
    NCT05144295
    Conditions
    Clinical Efficacy; Treatment Efficacy; Drug Side Effect
    Interventions
    Lubiprostone Pill; Lactulose Oral Liquid Product; Bisacodyl 5 MG; Sodium Picosulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2022-01-01
    Completion
    2022-11-01
    Enrolment
    274

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClinical Efficacy; Treatment Efficacy; Drug Side Effect
    InterventionLubiprostone Pill; Lactulose Oral Liquid Product; Bisacodyl 5 MG; Sodium Picosulfate
    PhasePhase 3
    Registry statusCompleted

  • A Study of Lubiprostone to Treat Constipation

    NCT04861233 · start 2021-09-01

    Registered record
    Registry ID
    NCT04861233
    Conditions
    Constipation
    Interventions
    No Intervention
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2021-09-01
    Completion
    2024-11-30
    Enrolment
    3,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionConstipation
    InterventionNo Intervention
    PhaseNot recorded
    Registry statusUnknown

  • Study of Comparative Effectiveness of Prucalopride and Lubiprostone in Constipation Predominant Irritable Bowel Syndrome

    NCT04985669 · start 2021-08-15

    Registered record
    Registry ID
    NCT04985669
    Conditions
    Patient Satisfaction
    Interventions
    Prucalopride 2mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2021-08-15
    Completion
    2022-03
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPatient Satisfaction
    InterventionPrucalopride 2mg
    PhasePhase 4
    Registry statusUnknown

  • Efficacy and Tolerability of Lubiprostone in Patients With Nonalcoholic Fatty Liver Disease

    NCT05768334 · start 2020-11-01

    Registered record
    Registry ID
    NCT05768334
    Conditions
    NAFLD
    Interventions
    Lubiprostone 24Mcg Oral twice daily
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-11-01
    Completion
    2023-02-01
    Enrolment
    116

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNAFLD
    InterventionLubiprostone 24Mcg Oral twice daily
    PhasePhase 3
    Registry statusCompleted

  • The Effect of Adding Lubiprostone to Standard Large-Volume PEG-ELS on The Quality of Inpatient Colonoscopy Preparation

    NCT04361656 · start 2020-05-01

    Registered record
    Registry ID
    NCT04361656
    Conditions
    Colonoscopy Preparation
    Interventions
    PEG-ELS current standard of care; PEG-ELS current standard of care plus Lubiprostone 24 microgram Oral Cap (x2)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Withdrawn
    Start
    2020-05-01
    Completion
    2021-02-04
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColonoscopy Preparation
    InterventionPEG-ELS current standard of care; PEG-ELS current standard of care plus Lubiprostone 24 microgram Oral Cap (x2)
    PhaseNot recorded
    Registry statusWithdrawn

  • Colon Preparation With 2L PEG in Combination With Lubiprostone vs 4L PEG

    NCT04138004 · start 2019-12-01

    Registered record
    Registry ID
    NCT04138004
    Conditions
    Indication for Modification of Patient Status (Diagnosis)
    Interventions
    polyethylene glycol in combination with lubiprostone; polyethylene glycol alone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-12-01
    Completion
    2021-07-30
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIndication for Modification of Patient Status (Diagnosis)
    Interventionpolyethylene glycol in combination with lubiprostone; polyethylene glycol alone
    PhasePhase 4
    Registry statusCompleted

  • Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation

    NCT03720613 · start 2019-01-04

    Registered record
    Registry ID
    NCT03720613
    Conditions
    Opioid-induced Constipation
    Interventions
    Naldemedine; Lubiprostone; Naloxegol
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2019-01-04
    Completion
    2030-11-01
    Enrolment
    34,532

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid-induced Constipation
    InterventionNaldemedine; Lubiprostone; Naloxegol
    PhaseNot recorded
    Registry statusRecruiting

  • Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo

    NCT03097861 · start 2017-03-13

    Registered record
    Registry ID
    NCT03097861
    Conditions
    Chronic Idiopathic Constipation
    Interventions
    Lubiprostone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-03-13
    Completion
    2017-08-17
    Enrolment
    552

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Idiopathic Constipation
    InterventionLubiprostone; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Lubiprostone for Chronic Idiopathic Constipation Treatment

    NCT02729909 · start 2016-05-11

    Registered record
    Registry ID
    NCT02729909
    Conditions
    Constipation
    Interventions
    Lubiprostone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-05-11
    Completion
    2017-06-05
    Enrolment
    211

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionConstipation
    InterventionLubiprostone; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Lubiprostone for Treatment of Chronic Idiopathic Constipation

    NCT02695719 · start 2016-04-14

    Registered record
    Registry ID
    NCT02695719
    Conditions
    Chronic Idiopathic Constipation
    Interventions
    Placebo; Lubiprostone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-04-14
    Completion
    2017-02-24
    Enrolment
    156

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Idiopathic Constipation
    InterventionPlacebo; Lubiprostone
    PhasePhase 3
    Registry statusCompleted

  • Evaluation of the Safety of Lubiprostone in Pediatric Participants Aged ≥ 6 Years to < 18 Years With Functional Constipation

    NCT02766777 · start 2016-04-12

    Registered record
    Registry ID
    NCT02766777
    Conditions
    Constipation - Functional
    Interventions
    Lubiprostone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-04-12
    Completion
    2016-11-04
    Enrolment
    87

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionConstipation - Functional
    InterventionLubiprostone
    PhasePhase 3
    Registry statusCompleted

  • Lubiprostone for the Treatment of Chronic Idiopathic Constipation

    NCT02651155 · start 2016-03-02

    Registered record
    Registry ID
    NCT02651155
    Conditions
    Constipation
    Interventions
    Lubiprostone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-03-02
    Completion
    2017-01-11
    Enrolment
    204

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionConstipation
    InterventionLubiprostone; Placebo
    PhasePhase 3
    Registry statusCompleted